

University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln

Papers in Veterinary and Biomedical Science

Veterinary and Biomedical Sciences,
Department of

1999

**PLASMID BEARING A CDNA COPY OF THE GENOME OF BOVINE
VIRAL DIARRHEA VIRUS, CHIMERIC DERIVATIVES THEREOF, AND
METHOD OF PRODUCING AN INFECTIOUS BOVINE WRAL
DIARRHEAVIRUS USING SAD PLASMID**

Ruben O. Donis

Ventzislav B. Vassilev

Follow this and additional works at: <https://digitalcommons.unl.edu/vetscipapers>



Part of the [Biochemistry, Biophysics, and Structural Biology Commons](#), [Cell and Developmental Biology Commons](#), [Immunology and Infectious Disease Commons](#), [Medical Sciences Commons](#), [Veterinary Microbiology and Immunobiology Commons](#), and the [Veterinary Pathology and Pathobiology Commons](#)

This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Papers in Veterinary and Biomedical Science by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.



US006001613A

United States Patent [19]

[11] **Patent Number:** **6,001,613**

Donis et al.

[45] **Date of Patent:** **Dec. 14, 1999**

[54] **PLASMID BEARING A CDNA COPY OF THE GENOME OF BOVINE VIRAL DIARRHEA VIRUS, CHIMERIC DERIVATIVES THEREOF, AND METHOD OF PRODUCING AN INFECTIOUS BOVINE VIRAL DIARRHEA VIRUS USING SAID PLASMID**

[75] Inventors: **Ruben O. Donis; Ventzislav B. Vassilev**, both of Lincoln, Nebr.

[73] Assignee: **Board of Regents of University of Nebraska**, Lincoln, Nebr.

[21] Appl. No.: **08/859,694**

[22] Filed: **May 21, 1997**

Related U.S. Application Data

[60] Provisional application No. 60/018,246, May 24, 1996.

[51] **Int. Cl.**⁶ **C12N 15/00**; C12N 7/00

[52] **U.S. Cl.** **435/91.4**; 435/91.21; 435/91.33; 435/235.1; 435/320.1

[58] **Field of Search** 435/69.3, 70.3, 435/91.1, 91.21, 91.33, 91.4, 235.1, 320.1; 536/23.1, 23.72

[56] References Cited

U.S. PATENT DOCUMENTS

4,719,177	1/1988	Baltimore et al.	435/91
4,992,367	2/1991	Cullen	435/69.52
5,206,163	4/1993	Renard et al.	435/240
5,670,152	9/1997	Weiner et al.	424/189.1

OTHER PUBLICATIONS

Brock et al., *Journal of Virological Methods*, 38:39–46, 1992.

Collett, et al., *Virology*, 165:191–199, 1988.

Ferrari, M., *Microbiologica*, 8:17–22, 1985.

Elaine T. Schenborn, et al., "A Novel Transcription Property of SP6 and T7 RNA Polymerases: Dependence on Template Structure," *Nucleic Acids Res.*, vol. 13, No. 17, 1985, pp. 6223–36.

Ruitang Deng, et al., "5' and 3' Untranslated Regions of Pestivirus Genome: Primary and Secondary Structure Analyses," *Nucleic Acids Res.*, vol. 21, No. 8, 1993, pp. 1949–1957.

Primary Examiner—Donna Wortman

Assistant Examiner—Brenda G. Brumback

Attorney, Agent, or Firm—Shook, Hardy & Bacon L.L.P.

[57]

ABSTRACT

A plasmid bearing a cDNA copy of the genome of bovine viral diarrhea virus (BVDV), chimeric derivatives of the plasmid and a method of producing an infectious bovine viral diarrhea virus using the plasmid are disclosed. The invention relates to a plasmid DNA molecule that replicates easily in *E. coli* and contains a sufficient portion of the genome of BVDV, cloned as cDNA, to be a suitable template to produce RNA in vitro which, upon transfection into bovine cells, gives rise to infectious BVDV. The BVDV created by the process of the invention can be engineered for use as a vector in many advantageous applications.

21 Claims, 10 Drawing Sheets




Fig. 1.




Fig. 2.

11

Fig. 2.
11




Fig. 3.
13





Fig. 3.

13







Fig. 4.
15



Complete digestion SacI, partial digestion NdeI, Fragment isolation, purification, CIAP treat.

Complete digestion SacI, partial digestion NdeI, Fragment isolation, purification, CIAP treat.






Fig. 6.

19



SmaI/Bsu36I - part. digested insert



Ligate to ClaI/DraIII digested vector. CIAP.

Fig. 6.




Fig. 7.

PLASMID	INSERT, SIZE	VECTOR	TOTAL
pBV 18	34-1308, 1274 bp	pUC 13	3954 bp
pBV 116	1111-3577, 2466 bp	pGEM 4	5337 bp
pBV D79	3061-4379, 1318 bp	pUC 9	3983 bp
pBV F2	4043-5181, 1138 bp	pUC 9	3803 bp
pBV SD2.3	5173-12542, 7369 bp	pGEM 4	9312 bp




Fig. 8.

**PLASMID BEARING A CDNA COPY OF THE
GENOME OF BOVINE VIRAL DIARRHEA
VIRUS, CHIMERIC DERIVATIVES
THEREOF, AND METHOD OF PRODUCING
AN INFECTIOUS BOVINE VIRAL
DIARRHEA VIRUS USING SAID PLASMID**

This application claims the benefit of U.S. Provisional Application No. 60/018,246 filed May 24, 1996.

**RIGHTS IN THE UNITED STATES
GOVERNMENT**

This invention was made with federal support under NRI grant 92-37204-7959 from the USDA. The United States government has certain rights to the invention.

BACKGROUND OF THE INVENTION

This invention relates to plasmids for viruses, methods for engineering the plasmids and methods for analyzing virus replication.

The bovine viral diarrhea virus, or BVDV, is the prototype species in the Pestivirus genus of the Flaviviridae. Positive strand RNA viruses, such as the poliovirus and the BVDV, have a genome consisting of a single molecule of RNA. Pure RNA extracted from either highly concentrated and purified poliovirus or BVDV can be transfected into a susceptible cell, which results in the production of infectious progeny virus by the cell. A homogeneous preparation of viral RNA molecules is infectious upon transfection.

The usefulness of RNA molecules from BVDV and poliovirus is limited because they are many thousand nucleotides in length and cannot be engineered in vitro to change their sequence using current technology. By contrast, DNA molecules of similar length, cloned into plasmids, can be manipulated with restriction enzymes and synthetic oligodeoxynucleotides to obtain any desired sequence.

It is known that the entire RNA sequence of some viruses can be cloned into a plasmid. Such plasmids can be used to produce RNA molecules in vitro that mimic the properties of the RNA extracted from the purified virus. The RNA synthesized in vitro using a plasmid DNA as a template produces the virus upon transfection into susceptible cells. Plasmids with this property are known as "infectious clones."

BVDV remains enzootic in cattle populations throughout the world. Current vaccines are either relatively unsafe or ineffective in control and eradication programs. Efficient reverse genetics approaches using an infectious molecular clone of the BVDV genome may contribute to the development of rationally-designed safe and efficacious vaccines.

The construction of an infectious molecular clone of BVDV, its subsequent modification to introduce a sequence tagged site and the production of a chimeric virus expressing a surface glycoprotein from a different strain, manipulating the BVDV genome in vitro and its potential effectiveness for reverse genetic analyses of pestivirus are described herein-after.

SUMMARY OF THE INVENTION

Accordingly, it is an object of the invention to provide a novel plasmid.

It is a further object of the invention to provide a novel method for engineering a plasmid.

It is a further object of the invention to provide a novel method for engineering the genome of BVDV for vaccine development.

It is a still further object of the invention to provide a novel method for the analysis of virus replication.

It is a still further object of the invention to provide a novel approach for vaccine development.

It is a still further object of the invention to provide a BVDV infectious clone.

BRIEF DESCRIPTION OF THE DRAWINGS

The above noted and other features of the invention will be better understood from the following detailed description, in which:

FIG. 1 is a block diagram illustrating the process of forming BVDV cDNA genomic clone;

FIG. 2 is a diagram of a portion of the process of FIG. 1; FIG. 3 is a diagram of another portion of the process of FIG. 1;

FIG. 4 is a diagram of another portion of the process of FIG. 1;

FIG. 5 is a diagram of another portion of the process of FIG. 1;

FIG. 6 is a diagram of another portion of the process of FIG. 1;

FIG. 7 is a table describing starting plasmids for the production of the chimeric virus of this invention; and

FIG. 8 is a diagram illustrating the nucleotide sequence alignment of the region of the BVDV genome between nucleotide 2040 and 3600 from 3 different viruses: the two parental and the chimeric derivative.

**DETAILED DESCRIPTION OF THE
INVENTION**

The present invention relates to a plasmid DNA molecule that replicates easily in *Escherichia coli* bacteria and contains a sufficient portion of the genome of BVDV, cloned as cDNA, to be a suitable template to produce RNA in vitro, which upon transfection into bovine cells, gives rise to infectious BVDV. The BVDV created by this process can be engineered as a vector for use in the following applications:

(1) the development of attenuated or avirulent virus strains for use as live vaccines;

(2) the addition of foreign sequences encoding proteins of immunological interest, such as proteins from other parasites or viruses, such as foot and mouth disease, leading to the use of BVDV as a vector to vaccinate against other infectious or parasitic diseases;

(3) the addition of immunostimulatory molecules, such as C3d complement molecule interleukins and the like;

(4) the development of marker vaccines with a characteristic deletion which allows the discrimination between vaccinated and infected animals by retrospective serological tests;

(5) the development of sequence-tagged BVDV vaccines which allow identification of the origin of the BVDV in the event of alleged vaccine-associated outbreaks;

(6) the mapping of attenuating mutations leading to avirulent phenotypes; and

(7) the identification of novel antiviral targets against pestivirus and related flaviviruses by creation of suitable chimeric viruses.

Five plasmids from the work of Collett et al., "Molecular Cloning and Nucleotide Sequence of the Pestivirus Bovine Viral Diarrhea Virus," *Virology* 165, 191-199, were used as a starting material for the present invention. Cultures of

these plasmids are maintained in several private cultures, one of which is in the refrigerator (Room VBS 151) in the Veterinary Basic Science Building, Department of Veterinary Science, University of Nebraska, Lincoln, Nebr. 68583, designated: (1) pBV-18; (2) pBV-116b; (3) pBV-D79; (4) pBV-F2; and (5) pBVSD2-3'. These cultures will be made available upon granting of the patent. These plasmids are described in FIG. 7.

From these plasmids, six vectors have been constructed: (1) a plasmid containing a chimeric genome of BVDV, strain NADL, with Singer strain E2/gp53 glycoprotein, propagated in *E. coli* strain GM119, culture designated as pVVNADL-Singp, maintained in a private repository at the campus of the University of Nebraska, in a refrigerator (Room VBS 151), in the Veterinary Basic Science Building, Department of Veterinary Science, Lincoln, Nebr. 68503 (ATCC No 97572); (2) a plasmid containing sequence-tagged genome of BVDV, strain NADL, in *E. coli* strain GM110, in a culture designated as pVVNADL delta Dra maintained in a private repository at the campus of the University of Nebraska, in a refrigerator (Room VBS 151), in the Veterinary Basic Science Building, Department of Veterinary Science, Lincoln, Nebr. 68503 (ATCC No. 97573); (3) a plasmid pVVNADL in a culture designated as pVVNADL maintained in a private repository at the campus of the University of Nebraska, in a refrigerator (Room VBS 151), in the Veterinary Basic Science Building, Department of Veterinary Science, Lincoln, Nebr. 68503; (4) a Chimeric BVDV, i-VVNADL-Singp, in a culture designated as i-VVNADL maintained in a private repository at the campus of the University of Nebraska, in a refrigerator (Room VBS 151), in the Veterinary Basic Science Building, Department of Veterinary Science, Lincoln, Nebr. 68503 (ATCC No. VR2529); (5) a virus i-VVNADL delta Dra in a culture designated as i-VVNADL delta Dra maintained in a private repository at the campus of the University of Nebraska, in a refrigerator (Room VBS 151), in the Veterinary Basic Science Building, Department of Veterinary Science, Lincoln, Nebr. 68503; and (6) a virus i-VVNADL in a culture designated as i-VVNADL maintained in a private repository at the campus of the University of Nebraska, in a refrigerator (Room VBS 151), in the Veterinary Basic Science Building, Department of Veterinary Science, Lincoln, Nebr. 68583.

Missing sequences were incorporated at four locations and the plasmids were joined to construct a single plasmid with the entire BVDV genome as cDNA: pVVNADL. An *E. coli*, strain GM119, (genotype: F-supE44 lacY1 galK2 galT22 metB1 dam-3 dcm-6 tsx-78 lambda-) was used in the preferred embodiment because of the increased plasmid stability provided by this *E. coli* strain. The infectious clone plasmid (pVVNADL) is not stable in some other *E. coli* hosts, such as MC1061, JM105, JM109, Sure, DH5a. The precise molecular basis of the increased stability in GM119 is unknown. The BVDV genome can be custom-tailored in the infectious clone plasmid pVVNADL, or one of its precursors: pBV18-F2 and p50Meu-3'. Two examples are as follows:

- (a) BVDV with a unique sequence tag, i-VVNADL delta Dra, was created which is neutral with respect to phenotypic properties of BVDV; and
- (b) a chimeric BVDV virus, i-VVNADL Singp, which replicates like a wild-type (WT) virus in spite of the chimeric nature of its genome and its antigenic differences detected with monoclonal antibodies.

As part of this process, the 5' and 3' termini of the BVDV genome were reconstructed. This reconstruction includes the addition of BVDV genomic sequences missing or corrupted,

the tailoring of signals of RNA transcription, and the engineering of cleavage sites for linearization of the DNA prior to transcription. A single nucleotide deletion present in the glycoprotein-encoding region of the virus (nt 2702) is repaired by replacement of a small fragment amplified from viral cDNA by RT-PCR. Sequence information present in all of the plasmids representing each region of the BVDV genome was verified and repaired.

Functional integrity of the T7 promotor, the 5'-UTR, and the ORF of one intermediate plasmid which encompasses the 5'-5.5 kb of the BVDV genome is verified by transfection of linearized pBV18-F2 plasmid DNA into bovine cells infected with a vaccinia virus producing T7 RNA polymerase. Because the T7 promoter in pBV18-F2 directs the synthesis of RNA transcripts representing the region of the BVDV genome encoding for the structural proteins of the virus, transfected bovine cells were probed with monoclonal antibodies (Mabs) to the viral glycoproteins. The integrity of the ORF was confirmed and it was determined that the 3' UTR of the virus is not required for translation. After this, a full-length cDNA clone, termed pVVNADL was obtained by joining a fragment of DNA derived from pBV18-F2 to plasmid P5DMeu-3'.

RNA transcripts from the full-length BVDV genome clones in pVVNADL were generated using the following procedure: DNA was linearized with SacII restriction endonuclease, which cleaves pVVNADL at the 3'-end of the BVDV genome. This DNA was used as template for in vitro transcription with T7 RNA polymerase with or without removing the 3'-overhand left by SacII. Transcription with the cap analog and transfection of the capped RNA were also tested. Production of RNA molecules identical to the BVDV genome with an exact 3' end was ascertained by gel electrophoresis and Northern Blotting. RNA synthesized in vitro was used to transfect EBTr cells by electroporation.

Controls included the electroporation of a transcription mix lacking template DNA or T7 DNA polymerase. Following electroporation, cells were distributed into dishes containing glass coverslips to allow fixation and immunofluorescence staining. Cells were monitored for possible signs of cytopathology. Monolayers on glass coverslips were fixed at 24 and 48 hours after electroporation and stained with Mab to the p80/N53 protein. Supernatant fluid from these wells was collected to check the phenotype of the rescued virus. RNA transcripts made in vitro were infectious, yielding $\sim 10^3$ TCID₅₀/μg. RNA transcribed in the presence of the cap analog had less infectivity than uncapped RNA. RNA synthesis with cap analog and reduced concentration of GTP very likely results in truncated transcripts. The phenotype of the virus rescued from pVVNADL transcripts, termed i-VVNADL, was studied in vitro.

Infectious BVDV was produced by cells transfected with uncapped RNA transcribed in vitro. The DNA template for RNA production consisted of a plasmid containing the entire genome of BVDV, cloned as cDNA. The internal ribosome entry site element in the 5'-untranslated region (UTR) of the viral genome and the functional 5'- and 3'- termini in viral genomic RNA BVDV rescued from the infectious cDNA clone had an in vitro phenotype virtually identical to the WT parent, the NADL strain of BVDV.

A genomic deletion of a single codon in the infectious clone, encoding glutamic acid at position 1600 of the viral polyprotein, gave rise to sequence tagged BVDV readily identified by restriction fragment length polymorphism analysis of reverse transcription-polymerase chain reaction (RT-PCR) amplicons. Suitability of the molecular clone of BVDV for genomic manipulations was shown by substituting

tion of the major envelope glycoprotein E2/gp53 with that of the Singer strain, giving rise to a chimeric virus. The predicted change in antigenic structure of the chimeric virus was identified with strain-specific Mabs by neutralization or immunofluorescence assay.

Embryonic bovine trachea (EBTr) cells and the NADL strain of BVDV were obtained from the American Type Culture Collection (CCL-44 and VR-534). This strain of BVDV was isolated from the spleen of a naturally-occurring fatal case of BVDV infection.

In this process, a set of five plasmids bearing overlapping cDNAs from the BVDV genome are used to assemble a full length copy of the viral genome in a single plasmid DNA molecule, following standard procedures. These five plasmids are the five plasmids maintained in five cultures in the refrigerator (Room VB5 151) in the Veterinary Basic Science Building, Department of Veterinary Science, University of Nebraska, Lincoln, Nebr. 68583 designated as pBV18, BV116b, pBVD79, pBVF2 and pBVSD2,3.

In FIG. 1, there is shown a flow diagram of an assembly process comprising seventeen intermediate cloning steps to join the original cDNA clones, to incorporate the missing 5'- and 3'- termini of the viral genome, to restore the altered BVDV genomic sequence, as well as to tailor signals for runoff RNA transcription *in vitro*.

As shown in FIG. 1, five plasmids pBV-18; pBV-116P; pBVD-79; pBV-F2; and pBVSD2-3' are converted to pBV18-T7-C1aI, pBV116-C1aI, pBVDF2-79 and pBVSD-3'-M1uI as shown in step 11, 13, 15 and 17 respectively. These five intermediate plasmids are converted to the plasmid pVVNADL.

In FIG. 2, there is shown a conversion of the pBV-18 plasmid to pBV18-T7-C1aI. In this process, the plasmid 12, pBV18, has a T7 promoter and missing nt added at 5'-end terminus of the BVDV genome in step 12. A T7 synthetic promoter flanked by EcoRI AvrII restrictive site cohesive ends is ligated (covalently bonded by DNA ligase) as shown by a plasmid 22, pBV18-T7. A unique C1aI site is added by ligating a synthetic oligonucleotide part at EcoRI-C1aIEcoRI to result in a plasmid 24, pBV18-T7-C1aI. This plasmid is digested with Bsu36I and MscI to obtain a DNA fragment, labeled 26 pBV18-T7-C1aI, which will be joined to a fragment derived from PBV106-F2 (plasmid 42 in FIG. 6).

In FIG. 3, there is shown a conversion of the plasmid 14, pBV116b, to the plasmid 32, pBV116-C1aI. In this process, plasmid 14 is modified by removal of DNA fragment extracting from the ECORV site to the REC II site, followed by replacement with an analogous fragment derived from BVDV RNA by RT-PCR. The reason to replace this fragment from this plasmid was the presence of a deletion at position 2702. The result of the experiment is plasmid 28, pBV116c. The plasmid 28 has modified by the insertion of a unique C1aI site. A XbaI-C1aI- XbaI synthetic oligonucleotide pair was ligated resulting in a plasmid 30, pBV116-C1aI. The plasmid 30 is treated by complete digestion with SacI, partial digestion in NdeI, followed by fragment isolation, purification, and CIAP treatment to result in a fragment 32, a linear fragment of pBV116-C1aI.*

In FIG. 4, there is shown a conversion of the plasmid 16, pBVD79, and the plasmid 18, pBVF2, to the plasmid 40pBVF2-D79. In this process, the plasmid 18, pBVF2 is treated by adding the missing nt at 3'-end to make overlapping with pBVSD2-3' and to restore the DraIII site from the NADL by ligating oligo EcoRV-DraIII-BamHI to result in a plasmid 34, pBVf2-DraIII. A plasmid 36, pBVF2-D79, is prepared by digesting a plasmid 16, pBVD79, with SmaI

and AvrII, purifying the insert fragment and with ligating into a window created in the plasmid 34, pBVF2-DraIII, by digesting with HindIII and blunting, then digesting with AvrII and followed by CIAP treatment. The plasmid 36 is treated by adding a unique SacI site. A synthetic oligonucleotide pair bearing a SacI site flanked by *E. coli* cohesive ends was ligated to form a plasmid 38, pBVF2-D79-SacI, which in turn is digested with NdeI and SacI. Purifying and inserting the fragment to result in a plasmid fragment 40, pBVF2-79. The plasmid 42 pBV116-F2, shown in FIG. 6, is prepared by combining and ligating plasmid fragment 32, shown in FIG. 3 and FIG. 6, pBV116-C1aI, modified by removal of a DNA fragment extracted from EcoRV site to the RsaII site, followed by replacement with an analogons fragment derived from BVDV RNA by RT-PCR and plasmid 40, pBVF2-D79 modified by removal of a DNA fragment extracted from EcoRV site to the RsaII site, followed by replacement with an analogons fragment derived from BVDV RNA by RT-PCR and ligating to a SacI NdeI (partly digested) vector to form the plasmid 42, pBV116-F2. A plasmid 44, pBV18-F2, is formed by combining the plasmid 26, pBV18-T7-C1aI modified by removal of a DNA fragment extracted from EcoRV site to the RsaII site, followed by replacement with an analogons fragment derived from BVDV RNA by RT-PCR, with the plasmid 42, pBV116-F2, using SmaI/Bsu36I (partly digested) ligated to Bsu36I/MscI digested vector.

In FIG. 5, there is shown the conversion of the plasmid 20, pBVSD2-3', to the plasmid 50, pBV5D3'-MCUI. In this process, a plasmid 46, pBVSD2.3-C1aI is prepared by ligating a synthetic DraIII-C1aI/XbaI-DraIII oligonucleotide in plasmid 20, pBVSD2-3', at a unique DraIII site. The plasmid 46, pBVSD2-3'-C1aI, has the oligonucleotide AatII-3'-end SacII-AatII introduced to restore the missing sequences at the 3'-end of RIBV5V genome to form a plasmid 48, bBVSD-3'. The plasmid 48, pBVSD-3' is converted to a plasmid 50, pBVSD-3'-M1uI by deleting the T7 promoter located between the C1oI and HseII sites. A synthetic oligonucleotide linker bearing on M1uI recognition site sequence flanked by ClaI and HaeII cohesive ends was cloned at this location. The plasmid 50 pBVSD-3'-M1uI is converted to the plasmid 52, pBVSD-3'-M1uI by digesting with DraIII and C1aI, and treating with CIAP.

Finally, in FIG. 6 there is shown the conversion of the plasmid 32, pBV116-C1aI, and the plasmid 40, pBVF2-D79, to the plasmid 54, pVV-NADL, which is 14,578 bp in length. The plasmid 54 is formed by combining the plasmid 44, pBV18-F2, with the plasmid 52, pBVSD-3'-M1uI. A purified C1aI DraIII insert from plasmid 44 was ligated into the plasmid 52 previously digested with C1aI/DraIII.

The resulting plasmid, pVVNADL, consists of the full-length cDNA of the BVDV genome flanked by an upstream T7 promoter which directs the start of transcription at nucleotide position 1. A SacII recognition sequence located at the end of the BVDV 3'-UTR allows production of positive sense RNA molecules of 12578 nucleotides by runoff transcription with T7 RNA polymerase. Introduction of a sequence tag into the BVDV genome was performed by digesting pVVNADL with DraIII and treating linear DNA with T4 DNA polymerase to remove the 3'-overhang. The blunt DNA was recircularized with T4 DNA ligase and the resulting pVVNADL Dra plasmid was sequenced to verify the three-nucleotide deletion.

To substitute a region of the BVDV, NADL, genome encoding the major envelope glycoprotein, transfer vector pVVNADL delta SA was constructed deletion of a SaII-AatII fragment from pVVNADL, comprising all the non-

structural protein-encoding region downstream of the SaII site (nucleotides 5621 to 12542). A PvuII-XcmI fragment of pVVNADL SA including E2/gp53 was replaced using standard methods with a homologous cDNA fragment derived from the Singer strain of BVDV by RT-PCR. The resulting pVVNADL SA-SINgp was digested with C1aI and DraIII to isolate a fragment representing the 5'-5184 nucleotides of the BVDV genome to be ligated to pSDM1u-3' digested with C1aI and DraIII to create the appropriate window. The resulting construct was designated pVVNADLSINgp and has Singer strain-derived genomic sequences from nucleotide position 2199 to 3497 replacing the original BVDV strain NADL sequences.

RNA transcripts were synthesized in vitro with T7 RNA polymerase from a template consisting of the full-length cDNA of the BVDV genome contained in pVVNADL linearized with SacII and treated with T4 to remove the 3'-overhang. The RNA was transcribed with bacteriophage T7 RNA polymerase under conditions adapted from the methods described in F. Ausubel, R. Brent, R. Kingston, J. Moore, J. Siedman, J. Smith & K. Struhl (1987) *Current Protocols in Molecular Biology* John Wiley and Sons, New York and E. T. Schenbom and R. C. Mierendorf, Jr., (1985) *Nucleic Acids Res* 13, 6223-36.

Transcription reaction products were analysed by gel electrophoresis and Northern analysis, using a probe derived from the 5'-end of the BVDV genome. RNA synthesized in vitro was digested with RNase-free DNase I, precipitated with isopropanol, washed in ethanol and used to transfect EBTr cells by electroporation as described below. Controls included the electroporation of a transcription mix lacking template DNA, or T7 RNA polymerase, or the use of a truncated subgenomic cDNA template (Sal digested). Electroporated cells were distributed into dishes containing glass coverslips to allow acetone fixation and immunostaining for fluorescence microscopy.

Integrity of the open reading frame (ORF) was assessed on Bovine Testicle (BT) cells infected with vaccinia MVA-T7 by transient transfection gene expression. Cells were fixed and probed for expression of E2/gp53 or NS23/p 125 with specific monoclonal antibodies (MAbs). RNA transfection was performed as follows:

Briefly, 3×10^6 EBTr cells resuspended in medium containing 3 μ g isopropanol-precipitated RNA were electroporated by two consecutive discharges of 1700 V/cm and 25 μ F in a 0.4 cm cuvette using a Gene Pulser instrument (Bio-Rad). RNA transfer efficiency was assessed by removing coverslips at 24 and 48 hours after plating and processing for immunofluorescence using a MAb to BVDV. Production of infectious progeny virus was assessed by harvesting culture medium from transfected monolayers, filtering through 0.45 μ m membranes and inoculation onto BT cells. Infection of BT cells was monitored by development of cytopathology and immunostaining with specific MAbs. Stocks of transfection-rescued virus were prepared after three in vitro passages to be used to determine genotype and phenotype.

Phenotype analyses of all plasmid-derived viruses were carried out on stocks prepared after three cell culture passages and included plaque morphology, as well as growth kinetics analyses at three incubation temperatures, 35° C., 37° C. and 39.5° C. by standard protocols. Antigenic analyses included seroneutralization assays and immunofluorescence probing using a panel of 9 MAbs which recognize E2/gp53 polymorphisms or conserved E0/gp48 epitopes. Bovine testicle cells were infected with BVDV at an input multiplicity of five and the monolayers lysed at 18 hours after infection for RNA extraction. RT PCR was performed

with appropriate synthetic oligodeoxynucleotide primer pairs. DNA amplified with Taq DNA polymerase was sequenced.

In summary, two plasmids were constructed, each carrying cDNA representing approximately the 5'- and 3'-halves of the BVDV genome. Plasmid pBV18-F2 consists of a T7 RNA polymerase promoter abutted to the viral 5'-UTR and adjacent polyprotein ORF sequences encoding the viral structural proteins. The second plasmid pBV50M1u-3' encompasses the nonstructural protein region and the 3'-UTR of the BVDV genome followed by a SacII restriction endonuclease site. These plasmids were used to join the two halves of the viral genome to give rise to a genomic-length construct termed pVVNADL.

The integrity and continuity of the polyprotein ORF was assessed by T7-driven transient expression of transfected pVVNADL DNA. Cells previously infected with vaccinia virus MVA-T7 expressing T7 RNA polymerase and transfected with pVVNADL DNA showed bright immunofluorescence following staining with MAbs to structural or nonstructural viral proteins, revealing expression of genuine BVDV proteins from an uninterrupted polyprotein ORF.

The plasmid carrying the entire genome of BVDV, pVVNADL, contains the Co1E1 replicon derived from pGEM4 and is 14,578 bases in length. The plating efficiency of *E. coli*, strain GM119 or JM109, hosts transfected with supercoiled pVVNADL DNA on ampicillin-containing solid medium is more than 100-fold lower than that of cells receiving pGEM4 DNA. *E. coli* strain GM119 proved to be a more suitable host for pVVNADL than strain JM109 which led to frequent DNA deletions.

Runoff RNA transcripts synthesized in vitro with phage T7 RNA polymerase from SacII-linearized pVVNADL were largely subgenomic in size with only a minor proportion of BVDV genome-length RNA molecules. Transfection of this unselected heterogeneous population of transcripts into EBTr cells by electroporation resulted in typical BVDV cytopathology, such as vacuolation and detachment from the matrix, after 72 hours. In contrast, EBTr cells transfected with truncated subgenomic transcripts processed in the same fashion did not show these changes. Expression of structural and nonstructural BVDV proteins was observed in 1-3% of the EBTr cell population as early as 24 hours after transfection by immunofluorescence with BVDV-specific MAbs. The proportion of positive cells rose to 10-20 percent by 48 hours following transfection.

Cell culture fluids were harvested periodically and used for the propagation of the rescued infectious virus on bovine testicle (BT) cells to carry out genetic and phenotypic characterization. Culture supernatants from EBTr cells transfected with pVVNADL-templated transcripts caused cytopathic changes in bovine testicle BT cells 48 hours after inoculation, while cell culture medium from control EBTr monolayers transfected with truncated transcripts had no effect. The antigenic phenotype of the virus rescued from pVVNADL transcripts, termed i-VVNADL, was identical to the parental NADL virus by immunofluorescence straining with a panel of MAbs against the E2/gp53 envelope glycoprotein and E0/gp48.

Growth parameters of the i-VVNADL at different temperatures were indistinguishable from parental BVDV NADL virus by plaque morphology and kinetics of growth determined at 35° C., 37° C., and 39.5° C. Thus, BVDV rescued from pVVNADL is essentially identical to the parental NADL strain of BVDV in vitro. Genetic manipulations of the NADL strain of BVDV involving the creation of BVDV cDNA plasmid intermediates propagated in *E. coli* does not alter the in vitro phenotype of the resulting i-VVNADL.

The introduction of a sequence tag into the BVDV genome allows unambiguous identification of the viruses rescued from plasmid-derived RNA transcripts and facilitates the interpretation of experimental data. The model tag should ideally be a unique sequence, readily identifiable by restriction fragment length polymorphism analysis and be neutral with respect to the viral phenotype. A deletion was introduced in the pVVNADL infectious clone which results in loss of a DraIII restriction enzyme recognition site and gain of a PmlI recognition site.

An infectious virus was rescued from pVVNADL Dra-templated transcripts with the same kinetics as with the intact WT cDNA infectious clone, the transfected cells showed a large proportion of infected cells by immunofluorescence of coverslips fixed at 48 hours. Characteristic vacuolating cytopathology could be observed in transfected cells between 72–96 hours after transfection and in subsequent passages of the culture medium onto new BT cells.

Restriction enzyme analysis of a 183 base pair amplicon spanning the DraIII site amplified by RT-PCR from i-VVNADL Dra revealed the presence of a PmlI site (CACGTG) and the absence of a Dram site (CACagaGTG). In contrast, DNA amplified from parental virus showed the reciprocal susceptibility to cleavage with these enzymes, characteristic of the NADL strain of BVDV. Antigenic analysis reveals that the i-VVNADL Dra virus is essentially identical to the parental NADL virus as ascertained by MAb analyses. Growth properties of i-VVNADL Dra analyzed in vitro were similar to those of WT. Thus, the single amino acid deleted from the vicinity of the putative cleavage site within p125/NS23 did not affect its viability and phenotype in vitro.

Reverse genetic approaches may be used to construct chimeras of viral genomic RNA for identification of genomic sequences responsible for a given phenotypic character. Antigenic chimeras of BVDV prototype NADL strain with the widely used strain Singer were constructed for this purpose. Unique markers are present exclusively in each of the two parental strains and were used to identify the newly created chimeric virus only if it carried both markers. One marker, a unique 270 base stretch of sequence derived from the cattle genome at position 4993, is characteristic of the NADL strain of BVDV. The other marker consisted of unique amino acid sequences of the E2/gp53 envelope glycoprotein which confer the Singer strain reactivity with Mabs 20, 31, 32, and 39 by immunoassay and neutralization. Thus, the Singer strain does not have the 270 nucleotide insert while the NADL strain fails to react with the selected set of four MAb.

By replacing the original envelope glycoprotein in the WT infectious clone with sequences coding for the Singer envelope genes, a chimeric virus which will carry the epitopes present in the Singer strain envelope and the 270 nucleotide bovine insert at position 4993 is obtained. The pVVNADL PvuII-XcmI fragment (position 2199 to 3497) which encodes for the C-terminus of E1/gp25 and the entire ectodomain of E2/gp53 was substituted with homologous sequences from the Singer strain of BVDV giving rise to plasmid pVVNADLSINgp. An infectious chimeric BVOV was recovered from transcripts derived from pVVNADLSINgp. Plaque morphology and growth kinetics of the chimeric virus, termed i-VVNADLSINgp, revealed that its growth properties are virtually identical to its parental NADL strain virus. By contrast, the antigenic properties of the chimeric virus depart from the BVDV strain NADL ancestor. The pattern of reactivity of proteins encoded by i-NADLSINgp with a panel of E2/gp53 with an antigenic

profile identical to the Singer isolate by immunofluorescence. Subtle differences were observed between these viruses in neutralization titers with Mabs 10 and 39, but the overall patterns remained the same.

The virus recovered from the parental pVVNADL cDNA has a gp53 indistinguishable from that of the NADL strain. Nucleotide sequence analyses of the i-VVNADLSINgp chimeric virus genomic RNA across the substituted fragment and the flanking regions reveals the chimeric structure of the genome. Furthermore, the 270 nucleotide bovine sequence insert at nucleotide 4993 characteristic of the NADL strain is present in i-VVNADLSINgp chimeric virus genomic RNA, as indicated by the size of the amplicon obtained by RT-PCR. Thus, the experimental evidence indicates that i-VVNADLSINgp represents a chimeric virus consisting of a genomic backbone from NADL strain of BVDV, but expressing the Singer strain E2/gp53 glycoprotein as well as the C-terminal end of E1/gp25.

The simple observation that uncapped RNA transcripts produced by T7 RNA polymerase from pVVNADL template establishes three concepts. The first concerns the structure of the 5'-end of the viral RNA. RNA without a 5'-cap structure was infectious, suggesting that a cap-independent translation initiation mechanism is used by BVDV genomic RNA for gene expression. This result is compatible with biochemical evidence suggesting that the 5'-end of genomic RNA was not blocked by inverted methylguanosine. The second concept emerges as a corollary of the first. An internal ribosome entry site element in the 5'-UTR of the BVDV genome identified in reticulocyte lysates must be functional during virus infection of cells. The third concept relates to the sequences of the extreme 5'- and 3'- termini of the viral RNA, thought to contain minus and plus strand RNA replicase promoter elements, respectively. Technical difficulties are commonly encountered in approaches to determine the 5'- and 3'- termini of large viral RNA molecules. However, the sequences reported by Deng and Brock, "5' and 3' Untranslated Regions of Pestivirus Genome: Primary and Secondary Structure Analyses," *Nucleic Acids Research*, 1993, Vol 21, No. 8, 1949–1957, and incorporated in pVVNADL gave rise to infectious virus with WT phenotype, indicating their functionality for the first time.

The 12,578 bases long genome of BVDV constitutes one of the largest known positive strand viral cDNA clone which yields infectious RNA transcripts. Moreover, the cDNA clone is replicated as a single plasmid in *E. coli*. The plating efficiency of *E. coli* hosts, such as strain JM109, transformed with pVVNADL and its derivatives and plated on ampicillin selective medium was reduced by at least 2 orders of magnitude as compared to the pGEM4 vector alone. In addition, a high frequency of deletions in transformant strain JM109 *E. coli* was observed. Instability of large cDNA clones is not uncommon and often determines utilization of alternative strategies involving generation of transcription DNA templates in vitro by ligation or long PCR. However, we found that certain strains of *E. coli*, notably GM119, circumvented such difficulties. The basis or biochemical correlates of the greater stability of pVVNADL in this host are unknown.

Full-length runoff transcripts were produced in vitro with low efficiencies by T7 RNA polymerase, apparently due to the intrinsic properties of the 12.5 kB pVVNADL template. Although the T7 RNA polymerase is highly processive for elongation of shorter transcripts, certain secondary structures in nascent transcripts can act as termination signals. The probability of such fortuitous events increases with transcript length. The presence of discrete subgenomic

length RNA molecules was sometimes observed in electropherograms of transcription reaction products. Low yields of full-length transcripts are not uncommon and also occur in other pestivirus cDNAs as shown for hog cholera virus in two independent reports. Unfractionated transcription products yielded infectious viruses readily upon transfection. Because only a relatively minor population of transcripts is full-length, it is likely to have a high specific infectivity. Others have reported considerably longer delays before an infectious virus is recovered from transfected monolayers.

The *in vitro* phenotype of the virus rescued from the pVVNADL as defined by the parameters and characteristics studied did not depart significantly from those of the parental BVDV strain NADL. Interestingly, shuttling of the large BVDV RNA genome through cDNA in a prokaryotic plasmid did not result in changes of the viral phenotype *in vitro*. Animal inoculation studies will be required to determine if the same is true of the *in vitro* phenotype of i-VVNADL. The wild-type nature of the virus rescued from pVVNADL makes it an ideal backbone to engineer changes leading to attenuation by reverse genetic approaches.

The high plasticity that characterizes RNA genomes makes it useful to design genomic tags that consist of more than single nucleotide changes to avoid reversion. However, large insertions or deletions may result in major decreases in replication fitness, favoring emergence of genomes repaired by RNA recombination. A deletion of three nucleotides (5182–5184: codon 1600) within the 270 nucleotide insert present in the NS23 coding region of the genome was used. Presence of this bovine sequence element at nucleotide 4993 is correlated with proteolytic processing of NS23, and the latter coincides with viral cytopathogenicity and virulence.

Infection of BT cells with the tagged i-VVNADL Dra virus resulted in cell death with the same kinetics and features of the parental strain. Thus, glutamic acid at position 1600 in the NADL strain polyprotein is not important for viral cytopathogenicity. However, this deletion resulted in a convenient restriction fragment length polymorphism tag providing a convenient means to discriminate between WT and tagged genomes. Although the virulence of this virus in cattle has not been determined experimentally (observed), its *in vitro* properties are identical to the WT. Therefore, i-VVNADL Dra constitutes a good candidate virus with a neutral genomic tag to further examine BVDV pathogenicity.

The glycoprotein chimera of BVDV displays a unique antigenic phenotype without alterations in replication properties *in vitro*. This virus can simply be traced using two markers: the unique epitopes present in E2/gp53 of the Singer strain of BVDV detected with specific Mabs (e.g.

10f9) and the presence of a unique 270 base pair bovine sequence insert after nucleotide 4993, detected by PCR, characteristic of the NADL parent and absent in the Singer genome.

Neutralization of virus infectivity by Mabs results from a high-affinity interaction between glycoprotein and antibody (K_a values between 10⁸ and 10¹⁰ 1.m01⁻¹). Even minor conformational changes in the viral glycoprotein can lower the affinity of the interaction (10⁶ to 10⁷ 1.m01⁻¹) and impair neutralization without preventing binding in immunoassays. Mabs 10 and 39 neutralized the chimeric virus to a lesser extent as compared to the WT BVDV Singer, suggesting extramolecular influences on the interaction between the Mab IgG and E2/gp53. For example, the structure of the E2/gp53 may be affected by association with a different E1/gp25 heterodimer partner in i-VVNADLSINGp leading to a decreased interaction affinity. Mabs 10 and 39 reacted with the chimeric virus in immunofluorescence assays, in accordance with the well established lower stringency of this assay.

Reverse genetics approaches can be used to introduce specific alterations or tags into the BVDV genome, as exemplified by the deletion of codon position 1600 (glutamic acid). Moreover, construction of chimeric virus is also feasible, as evidence by the expression of an envelope glycoprotein from a different BVDV strain. The two main approaches to explore gene function in positive strand RNA virus can now be implemented using infectious cDNA clones of BVDV.

Although the upper size limits of viable BVDV genomes are unknown, at least 2 KB of additional coding sequences can be part of viable virus. Consequently, it may be possible to use BVDV as a vector to express foreign proteins for immunization purposes. It will be of interest to determine if interspecies chimeras with other pestivirus or hepatitis C and G virus are viable. Precedents exist in picornavirus and flavivirus supporting the notion that different viral functional units can be substituted with those of distantly related virus. Notably, the hepatitis C internal ribosome entry site element is functional in poliovirus-hepatitis C chimeras (56). These chimeric approaches could lead to understanding of *in vitro* host range in pestivirus and hepatitis C virus. Finally, infectious clones could be used to engineer attenuating mutations leading to development of novel live vaccines.

Although a preferred embodiment of the invention has been described with some particularity, many modifications and variations of the preferred embodiment are possible in the light of the above teachings. It is to be understood that, within the scope of the appended claims, the invention can be practiced other than as specifically described.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 1

<210> SEQ ID NO 1

<211> LENGTH: 14578

<212> TYPE: DNA

<213> ORGANISM: bovine viral diarrhea virus

<400> SEQUENCE: 1

cacgcgtatc gatgaattcg ttaatacgcac tcactatagt atacgagaat tagaaaaggc 60

actcgtatc gtattggcca attaaaaata ataattagc ctagggaaca aatccctctc 120

agcgaagcc gaaaagagc tagccatgcc ctagtagga ctagcataat gaggggggta 180

-continued

gcaacagtgg	tgagttcgtt	ggatggctta	agccctgagt	acagggtagt	cgtcagtggg	240
tcgacgcctt	ggaataaagg	tctcagatg	ccacgtggac	gagggcatgc	ccaaagcaca	300
tcttaacctg	agcgggggtc	gcccaggtaa	aagcagtttt	aaccgactgt	tacgaataca	360
gcctgatagg	gtgtgcaga	ggcccactgt	attgctacta	aaaatctctg	ctgtacatgg	420
cacatggagt	tgatcaca	tgaactttta	tacaaaacat	acaacaaaa	accctcggg	480
gtggaggaac	ctgtttatga	tcaggcaggt	gatcccttat	ttggtgaaag	gggagcagtc	540
caccctcaat	cgacgctaaa	gctcccacac	aagagagggg	aacgcgatgt	tccaaccaac	600
ttggcatcct	tacaaaaaag	aggtgactgc	aggtcgggta	atagcagagg	acctgtgagc	660
gggtcttacc	tgaagccagg	gccactat	taccaggact	ataaaggctc	cgctctcac	720
agggccccg	tgagctcctt	tgaggaggga	tccatgtgtg	aaacgactaa	acggataggg	780
agagtaactg	gaagtgcagc	aaagctgtac	cacatttatg	tgtgtataga	tggatgtata	840
ataataaaaa	gtgccacgag	aagttaccaa	aggggtttca	ggtgggtcca	taataggctt	900
gactgccctc	tatgggtcac	aagttgctca	gacacgaaag	aagagggagc	aacaaaaaag	960
aaaacacaga	aaccgcagac	actagaaagg	gggaaaatga	aaatagtgcc	caaagaatct	1020
gaaaaagaca	gcaaaactaa	acctccggat	gctacaatag	tggtggaagg	agtcaaatac	1080
caggtgagga	agaagggaaa	aaccaagagt	aaaaacactc	aggacggctt	gtaccataac	1140
aaaaacaac	ctcaggaatc	acgcaagaaa	ctggaaaaag	cattgttggc	gtgggcaata	1200
atagctatag	ttttgtttca	agttacaatg	ggagaaaaca	taacacagtg	gaacctacaa	1260
gataatggga	cggaagggat	acaacgggca	atgttccaaa	ggggtgtgaa	tagaagttta	1320
catggaatct	ggccagagaa	aatctgtact	ggcgtccctt	cccatctagc	caccgatata	1380
gaactaaaa	caattcatgg	tatgatggat	gcaagtgaga	agaccaacta	cacgtgttgc	1440
agacttcaac	gccatgagtg	gaacaagcat	ggttgggtca	actggtacaa	tattgaacct	1500
tggtattctg	tcatgaatag	aacccaagcc	aatctcactg	agggacaacc	accaagggag	1560
tgcgcagtoa	cttgtaggtg	tgatagggct	agtgacttaa	acgtggtaac	acaagctaga	1620
gatagcccca	cacccttaac	aggttgcaag	aaaggaaaga	acttctcctt	tgacggcata	1680
ttgatgcggg	gccctgcgaa	ctttgaaata	gctgcaagtg	atgtattata	caaagaacat	1740
gaacgcatta	gtatgttaca	ggatctaact	ctttaccttg	ttgacgggtt	gaccaactoc	1800
ttagaaggtg	ccagacaagg	aaccgcctaa	ctgacaacct	ggttaggcaa	gcagctcggg	1860
atactaggaa	aaaagttgga	aaacaagagt	aagacgtggg	ttggagcata	cgctgcttcc	1920
ccttactgtg	atgtcgatcg	caaaattggc	tacatatggt	atacaaaaa	ttgcaccctt	1980
gcctgcttac	ccaagaacac	aaaaattgtc	ggccctggga	aatttgacac	caatgcagag	2040
gacggcaaga	tattacatga	gatggggggg	cacttgtcgg	aggtaactact	actttcttta	2100
gtggtgctgt	ccgacttcgc	accgaaaaca	gctagtgtaa	tgtaccta	actacat	2160
tccatcccc	aaagtcacgt	tgatgtaatg	gattgtgata	agaccagtt	gaacctcaca	2220
gtggagctga	caacagctga	agtaatacct	gggtcggctt	ggaactag	caaatatgta	2280
tgtataagac	caaattgggt	gccttatgag	acaactgtag	tgttggcatt	tgaagaggtg	2340
agccaggtgg	tgaagttagt	gttgagggca	ctcagagatt	taacacgcat	ttggaacgct	2400
gcaacaacta	ctgctttttt	agtatgcctt	gttaagatag	tcaggggcca	gatggtacag	2460
ggcattctgt	ggctactatt	gataacaggg	gtacaagggc	acttgattg	caaactgaa	2520
ttctcgtatg	ccatagcaaa	ggacgaaaga	attggtcaac	tgggggctga	aggccttacc	2580

-continued

accacttggga	aggaatactc	acctggaatg	aagctggaag	acacaatggt	cattgottgg	2640
tgcgaaagatg	ggaagttaat	gtacctccaa	agatgcacga	gagaaaccag	atatctcgca	2700
atcttgcata	caagagcctt	gccgaccagt	gtggtattca	aaaaactctt	tgatgggcga	2760
aagcaagag	atgtagtctga	aatgaacgac	aactttgaat	ttggactctg	cccatgtgat	2820
gccaaaccca	tagtaagag	gaagtccaat	acaacgctgc	tgaacggacc	ggccttccag	2880
atggtatgcc	ccataggatg	gacagggact	gtaagctgta	cgtcattcaa	tatggacacc	2940
ttagccacaa	ctgtggtacg	gacatataga	aggctaaac	cattccctca	taggcaaggc	3000
tgatcacccc	aaaagaatct	gggggagat	ctccataact	gcatccttgg	aggaaattgg	3060
acttgtgtgc	ctggagacca	actactatac	aaaggggct	ctattgaatc	ttgcaagtgg	3120
tggtgctatc	aatttaaaga	gagtgagga	ctaccacact	acccattgg	caagtgtaaa	3180
ttggagaacg	agactggta	caggctagta	gacagtacct	cttgcaatag	agaagggtg	3240
gccatagtac	cacaagggac	attaaagtgc	aagataggaa	aaacaactgt	acaggtcata	3300
gctatggata	ccaaactcgg	acctatgcct	tgacagccat	atgaaatcat	atcaagtgg	3360
gggcctgtag	aaaagacagc	gtgtacttct	aactacacta	agacattaa	aaataagtat	3420
tttgagccca	gagacagcta	ctttcagcaa	tacatgctaa	aaggagagta	tcaatactgg	3480
ttgacctgg	aggtgactga	ccatcaccgg	gattacttct	ctgagtcct	attagtgggtg	3540
gtagtagccc	tcttgggtg	cagatatgta	ctttggttac	tggttacata	catggtctta	3600
tcagaacaga	aggccttagg	gattcagtat	ggatcagggg	aagtgggtgat	gatgggcaac	3660
ttgctaacc	ataacaatat	tgaagtgtg	acatacttct	tgctgctgta	cctactgctg	3720
agggaggaga	gcgtaaagaa	gtgggtctta	ctcttatacc	acatcttagt	ggtacacca	3780
atcaaatctg	taattgtgat	cctactgatg	attggggatg	tggtaaaggc	cgattcaggg	3840
ggccaagagt	acttggggaa	aatagacctc	tgttttcaa	cagtagtact	aatcgtcata	3900
ggtttaatca	tagctaggcg	tgaccaact	atagtgccac	tggtaaacaat	aatggcagca	3960
ctgagggtoa	ctgaactgac	ccaccagcct	ggagttgaca	tcgctgtggc	ggtcatgact	4020
ataaccctac	tgatggttag	ctatgtgaca	gattatttta	gatataaaaa	atggttacag	4080
tgcatctcca	gcctggtatc	tgcggtgttc	ttgataagaa	gcctaataata	cctaggtaga	4140
atcgagatgc	cagaggtaac	tatcccaaac	tgagaccac	taactttaat	actattatat	4200
ttgatctcaa	caacaattgt	aacgaggtgg	aaggttgacg	tggtgtgcct	attgttgcaa	4260
tggtgtccta	tcttattgct	ggtcacaacc	ttgtgggccc	acttcttaac	cctaatactg	4320
atcctgccta	cctatgaatt	ggttaaatta	tactatctga	aaactgttag	gactgataca	4380
gaaagaagtt	ggctaggggg	gatagactat	acaagagttg	actccatcta	cgacgttgat	4440
gagagtggag	agggcgata	tctttttcca	tcaaggcaga	aagcacaggg	gaatttttct	4500
atactcttgc	cccttatcaa	agcaacactg	ataagttgcg	tcagcagtaa	atggcagcta	4560
atatacatga	gttacttaac	tttgactttt	atgtactaca	tgcacaggaa	agttatagaa	4620
gagatctcag	gaggtaccaa	cataatatcc	aggttagtgg	cagcactcat	agagctgaac	4680
tggtccatgg	aagaagagga	gagcaaaggc	ttaaagaagt	tttatctatt	gtctggaagg	4740
ttgagaaacc	taataataaa	acataaggta	aggaatgaga	ccgtggcttc	ttggtacggg	4800
gaggaggaag	tctacgggat	gccaaagatc	atgactataa	tcaaggccag	tacactgagt	4860
aagagcaggc	actgcataat	atgactgta	tgtagggccc	gagagtggaa	aggtggcacc	4920
tgcccaaaat	gtggacgcca	tggaagccg	ataacgtgtg	ggatgtcgct	agcagatttt	4980

-continued

gaagaaagac	actataaaag	aatctttata	aggaaggca	actttgagg	tatgtgcagc	5040
cgatgccagg	gaaagcatag	gaggttttaa	atggaccggg	aacctaagag	tgccagatac	5100
tgtgctgagt	gtaataggct	gcatcctgct	gaggaagggtg	acttttgggc	agagtcgagc	5160
atgttgggoc	tcaaaatcac	ctactttgcg	ctgatggatg	gaaagggtga	tgatatcaca	5220
gagtgggctg	gatgccagcg	tgtgggaatc	tcccagata	cccacagagt	cccttgtcac	5280
atctcatttg	gttcacggat	gcctttcagg	caggaataca	atggctttgt	acaatatacc	5340
gctagggggc	aactatttct	gagaaacttg	cccgtactgg	caactaaagt	aaaaatgctc	5400
atggttagca	accttgaga	agaaattggt	aatctggaac	atcttgggtg	gatcctaagg	5460
gggcctgccg	tgtgtaagaa	gatcacagag	cacgaaaaat	gccacattaa	tatactggat	5520
aaactaacgc	catttttcgg	gatcatgcca	agggggacta	caccagagc	cccgtgagg	5580
ttccctacga	gcttactaaa	agtgaggagg	ggtctggaga	ctgcctgggc	ttacacacac	5640
caagcgggga	taagttcagt	cgaccatgta	accgccgga	aagatctact	ggtctgtgac	5700
agcatgggac	gaactagagt	ggtttgcaa	agcaacaaca	ggttgaccga	tgagacagag	5760
tatggcgta	agactgactc	agggtgccca	gacggtgcca	gatgttatgt	gttaaatcca	5820
gaggccgtta	acatatcagg	atccaaaggg	gcagtcgttc	acctcaaaa	gacaggtgga	5880
gaattcacgt	gtgtcaccgc	atcaggcaca	ccggctttct	tcgacctaaa	aaactgaaa	5940
ggatggctag	gcttgctat	atttgaagcc	tccagcggga	gggtggttg	cagagtcaaa	6000
gtagggaaga	atgaagagtc	taaacctaca	aaaataatga	gtggaatcca	gaccgtctca	6060
aaaaacagag	cagacctgac	cgagatggtc	aagaagataa	ccagcatgaa	caggggagac	6120
ttcaagcaga	ttactttggc	aacaggggca	ggcaaaacca	cagaactccc	aaaagcagtt	6180
atagaggaga	taggaagaca	caagagagta	ttagttctta	taccattaag	ggcagcggca	6240
gagtcagctc	accagtatat	gagattgaaa	cacccaagca	tctcttttaa	cctaaggata	6300
ggggacatga	aagaggggga	catggcaacc	gggataacct	atgcatcata	cgggtacttc	6360
tgccaaatgc	ctcaaccaa	gctcagagct	gctatggtag	aatactcata	catattctta	6420
gatgaatacc	atttgccac	tcctgaacaa	ctggcaatta	tcgggaagat	ccacagattt	6480
tcagagagta	taagggttgt	cgccatgact	gccacgccag	cagggctcgt	gaccacaaca	6540
ggtcaaaagc	acccaataga	ggaattcata	gccccgagg	taatgaaag	ggagatctt	6600
ggtagtcagt	tccttgatat	agcaggggta	aaaataccag	tgatgagat	gaaaggcaat	6660
atgttggttt	ttgtaccaac	gagaaacatg	gcagtagagg	tagcaaagaa	gctaaaagct	6720
aagggctata	actctggata	ctattacagt	ggagaggatc	cagccaatct	gagagttgtg	6780
acatcacaat	cccctatgt	aatcgtggct	acaaatgcta	ttgaatcagg	agtgacacta	6840
ccagatttgg	acacggttat	agacacgggg	ttgaaatgtg	aaaagagggt	gagggatatca	6900
tcaaagatac	ccttcatcgt	aacaggcctt	aagaggatgg	ccgtgactgt	gggtgagcag	6960
gcgcagcgtg	ggggcagagt	aggtagagtg	aaaccggga	ggtattatag	gagccaggaa	7020
acagcaacag	ggtcaaagga	ctaccactat	gacctcttgc	aggcacaag	atacgggatt	7080
gaggatggaa	tcaacgtgac	gaaatccttt	agggagatga	attacgattg	gagcctatac	7140
gaggaggaca	gcctactaat	aaccagctg	gaaatactaa	ataatctact	catctcagaa	7200
gacttgccag	ccgctgttaa	gaacataatg	gccaggactg	atcaccagga	gccaatccaa	7260
cttgcataca	acagctatga	agtcagggtc	ccggtcctat	tccaaaaaat	aaggaatgga	7320
gaagtcacag	acacctacga	aaattactcg	tttctaaatg	ccagaaagtt	aggggaggat	7380

-continued

gtgcccggtg	atatctacgc	tactgaagat	gaggatctgg	cagttgacct	cttagggcta	7440
gactggcctg	atcctgggaa	ccagcaggtg	gtggagactg	gtaaagcact	gaagcaagtg	7500
accgggttgt	cctcggctga	aaatgcccta	ctagtggtctt	tatttgggta	tgtgggttac	7560
caggctctct	caaagagga	tgtcccaatg	ataacagaca	tatataccat	cgaggaccag	7620
agactagaag	acaccacca	cctccagtat	gcaccaacg	ccataaaaac	cgatgggaca	7680
gagactgaac	tgaagaact	ggcgtcgggt	gacgtggaaa	aaatcatggg	agccatttca	7740
gattatgcag	ctgggggact	ggagtttgtt	aatcccaag	cagaaaagat	aaaaacagct	7800
cctttgttta	aagaaaacgc	agaagccgca	aaagggtatg	tccaaaaatt	cattgactca	7860
ttaattgaaa	ataaagaaga	aataatcaga	tatggtttgt	ggggaacaca	cacagcacta	7920
tacaaaagca	tagctgcaag	actggggcat	gaaacagcgt	ttgccacact	agtgttaaag	7980
tggctagctt	ttggagggga	atcagtgta	gaccacgtca	agcaggcggc	agttgattta	8040
gtggtctatt	atgtgatgaa	taagccttcc	ttcccagggtg	actccgagac	acagcaagaa	8100
gggagcgcat	tcgtcgaag	cctgttcctc	tccgcactgg	caacctacac	atacaaaact	8160
tggaattacc	acaatctctc	taaagtgggt	gaaccagccc	tggcttacct	cccctatgct	8220
accagcgcat	taaaaatggt	cacccaacg	cggctggaga	gcgtggtgat	actgagcacc	8280
acgatataata	aaacatacct	ctctataag	aaggggaaga	gtgatggatt	gctgggtacg	8340
gggataagtg	cagccatgga	aatcctgtca	caaaaccag	tatcgtagg	tatatctgtg	8400
atgttggggg	taggggcaat	cgctgcgcac	aacgctattg	agtcagtgga	acagaaaagg	8460
accctactta	tgaagtggtt	tgtaaagaac	ttcttgatc	aggctgcaac	agatgagctg	8520
gtaaaagaaa	accagaaaa	aattataatg	gccttatttg	aagcagcca	gacaattggt	8580
aaccccctga	gactaatata	ccacctgtat	ggggttact	acaaagggtg	ggaggccaag	8640
gaactatctg	agaggacagc	aggcagaaac	ttattccat	tgataatggt	tgaagccttc	8700
gagttattag	ggatggactc	acaagggaaa	ataaggaacc	tgtccggaaa	ttacattttg	8760
gatttgatat	acggcctaca	caagcaaadc	aacagagggc	tgaagaaaat	ggtactgggg	8820
tggggccctg	caccctttag	ttgtgactgg	accctagtg	acgagaggat	cagattgcca	8880
acagacaact	atgtgaggtt	agaaaaccag	tgcccattgt	gctatgagat	gaaagctttc	8940
aaaaatgtag	gtggcaaac	taccaagtg	gagagagcg	ggcctttcct	atgtagaaac	9000
agacctggtg	ggggaccagt	caactacaga	gtcaccaagt	attacgatga	caacctcaga	9060
gagataaaac	cagtagcaaa	gttggaaagga	caggtagagc	actactacaa	aggggtcaca	9120
gcaaaaattg	actacagtaa	aggaaaaatg	ctcttgcca	ctgacaagtg	ggaggtggaa	9180
catggtgtca	taaccaggtt	agctaagaga	tatactgggg	tcgggttcaa	tgggtcatac	9240
ttaggtgacg	agcccaatca	ccgtgctcta	gtggagaggg	actgtgcaac	tataacaaa	9300
aacacagtac	agtttctaaa	aatgaagaag	gggtgtgcgt	tcacctatga	cctgacctc	9360
tccaatctga	ccaggctcat	cgaactagta	cacaggaaca	atcttgaaga	gaaggaaata	9420
cccaccgcta	cggctaccac	atggctagct	tacacctcg	tgaatgaaga	cgtagggact	9480
ataaaaccag	tactaggaga	gagagtaadc	cccgacctg	tagttgatat	caatttacia	9540
ccagaggtgc	aagtggacac	gtcagaggtt	gggatcacia	taattggaag	gaaaccctg	9600
atgacaacgg	gagtgacacc	tgtcttggaa	aaagtagagc	ctgacgccag	cgacaaccaa	9660
aactcgggtg	agatcgggtt	ggatgaggtt	aattaccag	ggcctggaat	acagacacat	9720
acactaacag	aagaaataca	caacagggat	gcgagccct	tcacatgat	cctgggctca	9780

-continued

aggaattcoa tatcaaatag ggcaaagact gctagaaata taaatctgta cacaggaaat 9840
 gacccccagg aaatacgaga cttgatggct gcagggcgca tgttagtagt agcactgagg 9900
 gatgtcgacc ctgagctgtc tgaatggctc gatttcaagg ggactttttt agatagggag 9960
 gccctggagg ctctaagtct cgggcaacct aaaccgaagc aggttaccac ggaagctggt 10020
 aggaatttga tagaacagaa aaaagatgtg gagatcccta actggtttgc atcagatgac 10080
 ccagtatctc tggaagtggc cttaaaaaat gataagtact acttagtagg agatgttggg 10140
 gagctaaaag atcaagctaa agcacttggg gccacggatc agacaagaat tataaaggag 10200
 gtaggctcaa ggacgtatgc catgaagcta tctagctggt tcctcaaggc atcaaacaaa 10260
 cagatgagtt taactccact gtttgaggaa ttgttgctac ggtgccacc tgcaactaag 10320
 agcaataagg ggcacatggc atcagcttac caattggcac agggtaactg ggagcccctc 10380
 ggttcggggg tgcacctagg tacaatacca gccagaaggg tgaagataca cccatatgaa 10440
 gcttacctga agttgaaaga tttcatagaa gaagaagaga agaaacctag ggttaaggat 10500
 acagtaataa gagagcacia caaatggata cttaaaaaa taaggtttca aggaaacctc 10560
 aacaccaaga aaatgctcaa cccagggaaa ctatctgaac agttggacag ggagggcgcc 10620
 aagaggaaca tctacaacca ccagattggt actataatgt caagtgcagg cataaaggctg 10680
 gagaatttgc caatagttag ggcacaaacc gacacaaaa cctttcatga ggcaataaga 10740
 gataagatag acaagatgta aaaccggcaa aatccagaat tgacaacaa attgttgagg 10800
 atttccaca cgatagccca acccaccctg aaacacacct acggtgaggt gacgtgggag 10860
 caacttgagg cgggggtaaa tagaaagggg gcagcaggct tcctggagaa gaagaacatc 10920
 ggagaagtat tggattcaga aaagcacctg gtagaacaat tggtcaggga tctgaaggcc 10980
 gggagaaaga taaaatatta tgaactgca ataccaaaa atgagaagag agatgtcagt 11040
 gatgactggc aggcagggga cctggtggtt gagaagaggc caagagtat ccaataccct 11100
 gaagccaaga caagcttagc catcactaag gtcactgata actgggtgaa acagcagccc 11160
 gttgtgattc caggatatga aggaaagacc ccctgttca acatcttga taaagtgaga 11220
 aaggaatggg actcgttcaa tgagccagtg gccgtaagtt ttgacaccaa agcctgggac 11280
 actcaagtga ctagtaagga tctgcaactt attggagaaa tccagaaata ttactataag 11340
 aaggaatggc acaagtcat tgacaccatc accgaccaca tgacagaagt accagttata 11400
 acagcagatg gtgaagtata tataagaaat gggcagagag ggagcggcca gccagacaca 11460
 agtgcctggc acagcatggt aaatgtcctg acaatgatgt acggcttctg cgaaagcaca 11520
 ggggtaccgt acaagatgtt caacaggggt gcaaggatcc acgtctgtgg ggatgatggc 11580
 ttcttaataa ctgaaaaagg gttagggctg aaatttgcta acaaagggat gcagattctt 11640
 catgaagcag gcaaacctca gaagataacg gaaggggaaa agatgaaagt tgcctataga 11700
 tttgaggata tagagttctg ttctcatacc ccagtcctg ttaggtggtc cgacaacacc 11760
 agtagtcaca tggccgggag agacaccgct gtgatactat caaagatggc aacaagattg 11820
 gattcaagtg gagagagggg taccacagca tatgaaaaag cggtagcctt cagtttcttg 11880
 ctgatgtatt cctggaacct gcttgtagg aggatttgcc tgttggtcct ttcgcaacag 11940
 ccagagacag acccatcaaa acatgccact tattattaca aaggatgacc aataggggcc 12000
 tataaagatg taataggtgc gaactaagt gaactgaaga gaacaggctt tgagaaattg 12060
 gcaaatctaa acctaagcct gtccacgttg ggggtctgga ctaagcacac aagcaaaaga 12120
 ataattcagg actgtgttgc cattgggaaa gaagagggca actggctagt taagcccagc 12180

-continued

aggctgatat ccagcaaac tggccactta tacatacctg ataaggctt tacattacaa 12240
 ggaaagcatt atgagcaact gcagctaaga acagagacaa acccggcat gggggttggg 12300
 actgagagat acaagttagg tcccatagtc aatctgctgc tgagaagggt gaaaattctg 12360
 ctcatgacgg ccgctcggcgt cagcagctga gacaaaatgt atatattgta aataaattaa 12420
 tccatgtaca tagtgtatat aaatatagtt gggaccgtcc acctcaaga gacgacacgc 12480
 ccaacacgca cagctaaaca gtagtcaaga ttatctacct caagataaca ctacatttaa 12540
 tgcacacagc actttagctg tatgaggata cgcccgacgt ctatagttgg actagggaaag 12600
 accttaaca gccccgcgg atctagagga gcatgacgacg tcaggtggca ctttctgggg 12660
 aaatgtgcgc ggaaccoccta ttgttttatt tttctaaata cattcaaata tgtatccgct 12720
 catgagacaa taacctgat aaatgcttca ataatttga aaaaggaaga gtatgagtat 12780
 tcaacatttc cgtgtcgcct ttattccctt ttttgcggca ttttgccttc ctgtttttgc 12840
 tcaccagaa acgctggtga aagtaaaaga tgctgaagat cagttgggtg cacgagtggg 12900
 ttacatcgaa ctggatctca acagcggtaa gatccttgag agttttcgcc ccgaagaacg 12960
 ttttccaatg atgagcactt ttaaagtctt gctatgtggc gcggtattat ccggtattga 13020
 cgccgggcaa gagcaactcg gtcgcgcgat acactattct cagaatgact tggttgagta 13080
 ctaccacgct acagaaaagc atcttacgga tggcatgaca gtaagagaat tatgacgtgc 13140
 tgccataacc atgagtgata aactgcggc caacttactt ctgacaacga tcggaggacc 13200
 gaaggagcta accgcttttt tgcaacaat gggggatcat gtaactcgcc ttgatcgttg 13260
 ggaaccggag ctgaatgaag ccataccaaa cgacgagcgt gacaccacga tgcctgtagc 13320
 aatggcaaca acgttgcgca aactattaac tggcgaacta cttactctag cttcccggca 13380
 acaattaata gactggatgg agcgggataa agttgcagga ccactctgc gctcggccct 13440
 tccgctggc tggtttattg ctgataaatc tggagccggg gagcgtgggt ctcgcggtat 13500
 cattgcagca ctggggccag atggttaagc ctcccgatc gtagttatct acacgacggg 13560
 gagtcaaggca actatgatg aacgaaatag acagatcgt gagatagggt cctcactgat 13620
 taagcattgg taactgtcag accaagtta ctcatatata ctttagattg atttaaaact 13680
 tcatttttaa tttaaaagga tctaggtgaa gatccttttt gataatctca tgacaaaat 13740
 cccttaacgt gagttttcgt tccactgagc gtcagacccc gtagaaaaga tcaaaggatc 13800
 ttcttgagat ctttttttc tgccgtaat ctgctgcttg caaacaaaa aaccaccgct 13860
 accagcggg gtttgtttgc cggatcaaga gotaccaact cttttccga aggtaactgg 13920
 cttcagcaga gcgagatgc caaatactgt cctctagtg tagccgtagt taggccacca 13980
 cttcaagaac tctgtagcac cgcctacata cctcgctctg ctaatcctgt taccagtggc 14040
 tgctgccagt ggcgataagt cgtgtcttac cgggttgac tcaagacgat agttaccgga 14100
 taaggcgcag cggctgggct gaacgggggg ttcgtgcaca cagcccagct tggagcgaac 14160
 gacctacacc gaactgagat acctacagc tgagctatga gaaagcgca cgcttcccga 14220
 agggagaaa gcggacaggt atccggtaag cggcagggtc ggaacaggag agcgcacgag 14280
 ggagcttcca ggggaaaac cctggtatct ttatagtcct gtcgggttc gccacctctg 14340
 acttgacgct cgatttttgt gatgctcgtc agggggcgag agcctatgga aaaacgccag 14400
 caacgcggcc tttttacggt tcctggcctt ttgctggcct tttgctcaca tgttctttcc 14460

-continued

 tgcgttatcc cctgattctg tgataaccg tattaccgcc tttgagtgcg ctgataccgc 14520

 tcgcccgcgc cgaacgaccg agcgcagcga gtcagtgcgc gaggaagcgg aagagcgc 14578

The following is claimed:

1. A method of producing recombinantly engineered infectious bovine viral diarrhoea virus comprising:
 - providing a vector comprising a reverse transcribed copy of bovine viral diarrhoea virus RNA;
 - recombinantly engineering the reverse transcribed copy of the bovine viral diarrhoea virus;
 - transforming an *E. coli* with the vector;
 - causing the transformed host cell to produce a plurality of vectors;
 - extracting the plurality of vectors from the transformed host cell;
 - forming a plurality of synthesized RNA from the plurality of vectors comprising the reverse transcribed copy of the bovine viral diarrhoea virus RNA;
 - introducing the synthesized RNA into a mammalian cell; and
 - recovering the recombinantly engineered infectious bovine viral diarrhoea virus from the mammalian cell.
2. The method of claim 1 wherein the *E. coli* is strain GM119.
3. The method of claim 1 wherein the step of introducing the bovine viral diarrhoea virus RNA into the mammalian cell utilizes electroporation.
4. The method of claim 1 wherein the mammalian cell is an embryonic bovine tracheal cell.
5. The method of claim 1 wherein the vector comprises pVVNADL-SINgp.
6. The method of claim 1 wherein the vector contains a selective marker for transformed cells.
7. The method of claim 1 wherein the vector comprises pVVNADLADra.
8. A method of producing recombinantly engineered infectious bovine viral diarrhoea virus comprising:
 - providing a vector comprising a reverse transcribed copy of bovine viral diarrhoea virus RNA;
 - recombinantly engineering the reverse transcribed copy of the bovine viral diarrhoea virus to form a recombinantly engineered vector;
 - transforming *E. coli*, strain GM119, with the recombinantly engineered vector;
 - causing the transformed *E. coli* to produce a plurality of the recombinantly engineered vectors;
 - extracting the plurality of recombinantly engineered vectors from the transformed *E. coli*;
 - forming a plurality of synthesized RNA from the plurality of recombinantly engineered vectors comprising the reverse transcribed copy of bovine viral diarrhoea virus RNA;
 - introducing the synthesized RNA into an embryonic bovine tracheal cell by electroporation; and
 - recovering the recombinantly engineered infectious bovine viral diarrhoea virus.
9. A method of isolating a plurality of recombinantly engineered bovine viral diarrhoea virus comprising:
 - providing a vector comprising a reverse transcribed copy of a genome of bovine viral diarrhoea virus RNA;
 - creating a recombinantly engineered infectious bovine viral diarrhoea virus;
 - causing a host cell to produce a plurality of recombinantly engineered infectious bovine viral diarrhoea virus; and
 - isolating the plurality of recombinantly engineered infectious bovine viral diarrhoea virus.
10. A method of producing recombinantly engineered infectious bovine viral diarrhoea virus comprising:
 - providing a pVVNADL;
 - recombinantly engineering pVVNADL to form a recombinantly engineered pVVNADL;
 - transforming *E. coli*, strain GM119, with the recombinantly engineered pVVNADL to form a transformed *E. coli*;
 - causing the transformed *E. coli* to produce a plurality of the recombinantly engineered pVVNADL;
 - extracting the plurality of recombinantly engineered pVVNADL from the transformed *E. coli*;
 - forming a plurality of synthesized RNA from the plurality of recombinantly engineered pVVNADL;
 - introducing the plurality of synthesized RNA into an embryonic bovine tracheal cell by electroporation; and
 - recovering the recombinantly engineered infectious bovine viral diarrhoea virus.
11. An isolated vector adapted to produce recombinantly engineered infectious bovine viral diarrhoea virus.
12. The vector of claim 11, further comprising a sequence tag.
13. A chimeric vector comprising a 270 nucleotide insert and an envelope glycoprotein from Singer strain bovine viral diarrhoea virus wherein the vector is adapted to produce a chimeric infectious bovine viral diarrhoea virus.
14. The vector of claim 13 wherein the vector comprises pVVNADL-SINgp.
15. The vector of claim 13, wherein the synthesized RNA is introduced into EBTr cells.
16. An isolated vector comprising sequence ID. NO. 1.
17. A vector comprising pVVNADL-SINgp.
18. A vector comprising pVVNADLADra.
19. A chimeric virus comprising i-VVNADL-SINgp.
20. A recombinant bovine viral diarrhoea virus comprising i-VVNADLADra.
21. A plurality of recombinantly engineered infectious bovine viral diarrhoea virus produced by the process comprising:
 - providing a vector comprising a reverse transcribed copy of a genome of bovine viral diarrhoea virus RNA;
 - creating a recombinantly engineered infectious bovine viral diarrhoea virus;
 - causing a host cell to produce a plurality of recombinantly engineered infectious bovine viral diarrhoea virus; and
 - isolating the plurality of recombinantly engineered infectious bovine viral diarrhoea virus.

* * * * *